You're signed outSign in or to get full access.
Aisling Capital Management LP
Aisling Capital Management LP is a New York-based hedge fund founded in 2000, focused on investing in life sciences companies with an emphasis on pharmaceuticals, medical products, and healthcare innovation. The firm manages public and private investments and serves institutional investors, endowments, and high-net-worth individuals. It is known for deep sector expertise and a rigorous approach to healthcare investing. The firm has approximately 12 employees, with two-thirds in investment roles.
Investment Strategy
Aisling Capital Management LP specializes in investing primarily in the life sciences sector, with a focus on pharmaceuticals, biotechnology, and healthcare companies. The firm employs a fundamental research-driven strategy, targeting both public and private companies positioned for growth through clinical development, regulatory milestones, and commercial launches. The fund's philosophy emphasizes concentrated, high-conviction positions, particularly in innovative therapeutics and medical technologies.
Latest 13F Filing Activity
Aisling Capital Management LP filed their most recent 13F report on Jun 30, 2025 disclosing 13 equity positions with a total 13F market value of $360M. The fund increased holdings in Bridgebio Pharma Inc. (bbio), Verona Pharma PLC (vrna), Biomea Fusion Inc. (bmea) among other positions. Aisling Capital Management LP reduced exposure to Bicara Therapeutics Inc. (bcax), Syndax Pharmaceuticals, Inc. (sndx), Monte Rosa Therapeutics Inc. (glue) among others.
Top Holdings
Equity Positions (13)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
B BBIO | BridgeBio Pharma Inc. (BBIO) | 72.85% | $262.0M | 6,068,125 | $39.14 | $43.18 | +$52.2M |
V VRNA | Verona Pharma plc (VRNA) | 16.18% | $58.2M | 615,352 | $7.38 | $94.58 | +$19.1M |
S SNDX | Syndax Pharmaceuticals, Inc. (SNDX) | 3.43% | $12.3M | 1,316,806 | $11.05 | $9.37 | -$261.7K |
G GLUE | Monte Rosa Therapeutics Inc (GLUE) | 1.85% | $6.6M | 1,472,331 | $22.70 | $4.51 | -$191.4K |
B BCAX | Bicara Therapeutics Inc. (BCAX) | 1.47% | $5.3M | 568,919 | $25.47 | $9.29 | -$2.1M |
Industry Allocation
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more